Newsfile Corp
18 Jul 2026, 10:25 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo study failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a Phase III trial for a key drug candidate directly reduces the company's future revenue potential and pipeline value.
-0.80A federal securities class action lawsuit has been filed against Regeneron alleging that executives made false or misleading statements regarding the Fianlimab-Libtayo study. — Securities litigation introduces legal risk, potential financial settlements, and reputational damage to management.
-0.40The lawsuit claims Regeneron concealed that the study's preliminary statistical assumptions were fundamentally flawed and that the treatment failed to show meaningful clinical differentiation. — Allegations of intentional concealment and flawed data undermine investor confidence in the company's clinical reporting and governance.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a federal securities class action lawsuit following the failure of a Phase III clinical trial and allegations of misleading statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
